Photoimmunotherapy and Irradiance Modulation Reduce Chemotherapy Cycles and Toxicity in a Murine Model for Ovarian Carcinomatosis: Perspective and Results
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Photoimmunotherapy and Irradiance Modulation Reduce Chemotherapy Cycles and Toxicity in a Murine Model for Ovarian Carcinomatosis: Perspective and Results
Authors
Keywords
-
Journal
ISRAEL JOURNAL OF CHEMISTRY
Volume 52, Issue 8-9, Pages 776-787
Publisher
Wiley
Online
2012-09-14
DOI
10.1002/ijch.201200016
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Synthesis and photobiological study of a novel chlorin photosensitizer BCPD-18MA for photodynamic therapy
- (2011) Jialiang Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Photodynamic therapy of cancer: An update
- (2011) Patrizia Agostinis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A Phase I Clinical Trial of Safingol in Combination with Cisplatin in Advanced Solid Tumors
- (2011) M. A. Dickson et al. CLINICAL CANCER RESEARCH
- Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer
- (2011) Janelle M. Fauci et al. GYNECOLOGIC ONCOLOGY
- Targeted photodynamic therapy – a promising strategy of tumor treatment
- (2011) Andrzej M. Bugaj PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES
- A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer
- (2010) Jalid Sehouli et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Synergistic Enhancement of Carboplatin Efficacy with Photodynamic Therapy in a Three-Dimensional Model for Micrometastatic Ovarian Cancer
- (2010) I. Rizvi et al. CANCER RESEARCH
- Farletuzumab in epithelial ovarian carcinoma
- (2010) Whitney A Spannuth et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074)
- (2010) Patricia Pautier et al. GYNECOLOGIC ONCOLOGY
- Optimal Management of Recurrent Ovarian Cancer
- (2010) Maurie Markman INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Quantitative imaging reveals heterogeneous growth dynamics and treatment-dependent residual tumor distributions in a three-dimensional ovarian cancer model
- (2010) Jonathan P. Celli et al. JOURNAL OF BIOMEDICAL OPTICS
- EGFR Signaling and Drug Discovery
- (2010) Georg Lurje et al. ONCOLOGY
- Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
- (2010) Maurie Markman Therapeutics and Clinical Risk Management
- A Current Review of Targeted Therapeutics for Ovarian Cancer
- (2010) Susana M. Campos et al. Journal of Oncology
- Detecting Epidermal Growth Factor Receptor Tumor Activity In Vivo During Cetuximab Therapy of Murine Gliomas
- (2009) Summer L. Gibbs-Strauss et al. ACADEMIC RADIOLOGY
- Novel strategies for reversing platinum resistance
- (2009) Mian M.K. Shahzad et al. DRUG RESISTANCE UPDATES
- EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma
- (2009) Laurie G Hudson et al. Future Oncology
- Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer
- (2009) Ming-Shien Yen et al. GYNECOLOGIC ONCOLOGY
- Ovarian cancer
- (2009) Bryan T Hennessy et al. LANCET
- Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence
- (2009) Wim P. Ceelen et al. Nature Reviews Clinical Oncology
- Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions
- (2009) Lainie P. Martin et al. SEMINARS IN ONCOLOGY
- Targeting the EGF Receptor for Ovarian Cancer Therapy
- (2009) Reema Zeineldin et al. Journal of Oncology
- Ovarian Cancer
- (2008) Kathleen R. Cho et al. Annual Review of Pathology-Mechanisms of Disease
- Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
- (2008) Z Tang et al. BRITISH JOURNAL OF CANCER
- Matrix Metalloproteinase 9 Is a Mediator of Epidermal Growth Factor-Dependent E-Cadherin Loss in Ovarian Carcinoma Cells
- (2008) K. D. Cowden Dahl et al. CANCER RESEARCH
- Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression
- (2008) Laurie G. Hudson et al. CLINICAL & EXPERIMENTAL METASTASIS
- A Phase I Trial of Pemetrexed Plus Gemcitabine Given Biweekly with B-Vitamin Support in Solid Tumor Malignancies or Advanced Epithelial Ovarian Cancer
- (2008) M. L. Hensley et al. CLINICAL CANCER RESEARCH
- Combination of Photodynamic Therapy with Anti-Cancer Agents
- (2008) M.-F. Zuluaga et al. CURRENT MEDICINAL CHEMISTRY
- Pharmaceutical Management of Ovarian Cancer
- (2008) Maurie Markman DRUGS
- Photosensitiser delivery for photodynamic therapy. Part 2: systemic carrier platforms
- (2008) Stéphane A Sibani et al. Expert Opinion on Drug Delivery
- Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
- (2008) Halla S. Nimeiri et al. GYNECOLOGIC ONCOLOGY
- A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
- (2008) Jason Konner et al. GYNECOLOGIC ONCOLOGY
- Combination Chemotherapy and Photodynamic Therapy with Fab′ Fragment Targeted HPMA Copolymer Conjugates in Human Ovarian Carcinoma Cells
- (2008) Jarunee Hongrapipat et al. MOLECULAR PHARMACEUTICS
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started